Hepatic artery infusion chemotherapy for liver malignancy. Review uri icon

Overview

abstract

  • To date, hepatic artery infusion (HAI) chemotherapy has primarily been investigated in the setting of colorectal cancer liver metastases (CRLM). Few studies have been conducted in North America regarding HAI chemotherapy for primary liver cancers (PLC) or noncolorectal liver metastases (non-CRLM). Despite decades of evaluation, controversy surrounding the use of HAI chemotherapy still exists. In this article the methods of HAI chemotherapy delivery, technical aspects of catheter and pump insertion, and specific complications of HAI chemotherapy are discussed. Outcomes of clinical trials and reviews of HAI chemotherapy in the setting of CRLM, PLC, and non-CRLM are evaluated.

publication date

  • October 14, 2014

Research

keywords

  • Antineoplastic Agents
  • Hepatic Artery
  • Infusions, Intra-Arterial
  • Liver Neoplasms

Identity

Scopus Document Identifier

  • 84922933404

Digital Object Identifier (DOI)

  • 10.1016/j.soc.2014.09.005

PubMed ID

  • 25444472

Additional Document Info

volume

  • 24

issue

  • 1